KRI and KPI Prioritization for Life Sciences Industry from Business Intelligence
##plugins.themes.academic_pro.article.main##
Abstract
Life Sciences industry today faces a critical challenge when it comes to risk tacking and risk prioritization in the Phase 3 of clinical trials. Pharmaceutical companies have huge volumes of data that is gathered over the span of the trial, and even more detailed data during the human drug testing phase. The data collected is huge in volume, the analysis of this humungous data and finding the pain points ID of the biggest challenges this industry faces.